DaVita (DVA) FY2025 10-K Annual Report
DaVita (DVA) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 11, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
DaVita FY2025 10-K Analysis
Business Overview
- • Core business: Providing kidney care services with significant revenues from commercial insurance and government programs like Medicare, Medicaid, and Veterans Affairs
- • New emphasis: Expansion in integrated kidney care offerings including home-based dialysis, U.S. integrated kidney care business, and ancillary services
Management Discussion & Analysis
- • No revenue or profitability figures disclosed in provided MD&A section
- • Forward-looking risks include reimbursement rate declines, patient mix shifts, and increased competition pressures
Risk Factors
- • Legal risk: accrual for potential third-party judgment costs of $25 million for unspecified legal matters
- • Macroeconomic exposure: $10.16 billion long-term debt principal maturity with $5.29 billion due after 2030
DaVita FY2025 Key Financial MetricsXBRL
Revenue
$13.6B
▲ +6.5% YoY
Net Income
$747M
▼ -20.2% YoY
Operating Margin
15.0%
▼ -133bp YoY
Net Margin
5.5%
▼ -183bp YoY
ROE
-114.7%
▼ -88776bp YoY
Total Assets
$17.5B
▲ +1.1% YoY
EPS (Diluted)
$9.84
▼ -8.3% YoY
Operating Cash Flow
$1.9B
▼ -6.7% YoY
Source: XBRL data from DaVita FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on DaVita
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.